Annexon is a biopharmaceutical company developing targeted immunotherapies that inhibit the classical complement pathway at the C1q initiation point to treat neuroinflammatory, neurodegenerative, and ophthalmologic diseases affecting millions of patients globally. The company's lead candidate is tanruprubart, an anti-C1q antibody in Phase 3 development for Guillain-Barré Syndrome and other neurological conditions, while vonaprument, an intravitreal C1q inhibitor, is being studied for geographic atrophy, a major cause of blindness. Annexon generates no current revenue as a development-stage company but plans to commercialize approved products either independently or through licensing partnerships with larger biopharmaceutical companies, with all manufacturing contracted to third parties.